ArticleFrontiers in oncology2021

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Ying Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.